We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
-3.66%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$625M
AUM Growth
+$69M
Cap. Flow
+$102M
Cap. Flow %
16.39%
Top 10 Hldgs %
88.98%
Holding
21
New
6
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ELEV
Elevation Oncology
ELEV
+$35M
2
GLUE icon
Monte Rosa Therapeutics
GLUE
+$30M
3
BMEA icon
Biomea Fusion
BMEA
+$14.1M
4
TRML
Tourmaline Bio
TRML
+$10.5M
5
OKUR
OnKure Therapeutics
OKUR
+$9.88M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$370M 59.23%
6,068,125
– –
ELEV
2
DELISTED
Elevation Oncology
ELEV
$38.5M 6.16%
+2,834,910
New +$35M
GLUE icon
3
Monte Rosa Therapeutics
GLUE
$1.4B
$33.4M 5.35%
+1,472,331
New +$30M
HRMY icon
4
Harmony Biosciences
HRMY
$2.04B
$23.8M 3.81%
842,815
– –
NUVB icon
5
Nuvation Bio
NUVB
$2.2B
$23.7M 3.79%
2,541,009
– –
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$1.69B
$17.6M 2.82%
1,025,000
– –
SPRB
7
Spruce Biosciences
SPRB
$118M
$13.5M 2.16%
16,073
– –
BMEA icon
8
Biomea Fusion
BMEA
$84.6M
$12.5M 2%
+798,757
New +$14.1M
SYRE icon
9
Spyre Therapeutics
SYRE
$8.54B
$11.8M 1.88%
67,646
– –
ACRS icon
10
Aclaris Therapeutics
ACRS
$726M
$11.1M 1.78%
634,455
– –
PSTX
11
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$10.5M 1.67%
1,043,267
– –
TRML
12
DELISTED
Tourmaline Bio
TRML
$10M 1.61%
+68,292
New +$10.5M
TECX
13
Tectonic Therapeutic
TECX
$529M
$8.98M 1.44%
84,148
– –
MRKR icon
14
Marker Therapeutics
MRKR
$18.8M
$8.77M 1.4%
314,286
– –
VRNA
15
DELISTED
Verona Pharma
VRNA
$8.71M 1.4%
1,332,485
– –
OKUR
16
OnKure Therapeutics
OKUR
$154M
$8.27M 1.32%
+88,608
New +$9.88M
OBSV
17
DELISTED
ObsEva SA Ordinary Shares
OBSV
$4.2M 0.67%
1,386,338
– –
BCEL
18
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$3.3M 0.53%
387,653
– –
VIRX
19
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.27M 0.52%
+288,571
New +$2.9M
ZSAN
20
DELISTED
Zosano Pharma Corporation
ZSAN
$2.58M 0.41%
77,664
– –
NBRV
21
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$258K 0.04%
7,641
– –

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Aisling Capital Management held 21 positions worth $625M, up 12% from $556M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Aisling Capital Management deployed $102M of net new capital in Q2 2021, opening 6 new positions. Its largest new stake was Elevation Oncology: 2,834,910 shares worth $38.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management's largest Q2 2021 buy was Elevation Oncology: 2,834,910 shares worth $38.5M.
  • Aisling Capital Management's ten largest holdings make up 89% of its $625M portfolio in Q2 2021.
  • Aisling Capital Management opened 6 new positions and closed 0 in Q2 2021.
  • Aisling Capital Management's portfolio value rose 12% quarter-over-quarter to $625M.

Based on Aisling Capital Management's 13F filing for Q2 2021, filed 6 Aug 2021.